Literature DB >> 29058758

Features of 921 Patients With Spinal Tuberculosis: A 16-Year Investigation of a General Hospital in Southwest China.

Yuan Yao, Weilin Song, Kuiyou Wang, Bingtao Ma, Huan Liu, Wenjie Zheng, Yu Tang, Yue Zhou.   

Abstract

Southwest China has a high burden of spinal tuberculosis (TB). Few large case studies of spinal TB in southwest China have been conducted. This study investigated the features of 921 patients who were treated for spinal TB at a general hospital in southwest China between 2001 and 2016. Demographic data, clinical data, laboratory data, imaging findings, treatment methods, and outcomes of patients who were admitted to the hospital for spinal TB were reviewed retrospectively. The annual incidence of spinal TB increased throughout the study period. The greatest number of patients were 41 to 50 years old (22.04%). Local pain was the most common symptom (97.8%). A significant difference in the duration of symptoms was observed between rural populations (28.40 months) and urban populations (10.17 months) (P=.041). Of the patients, 32.68% had a normal erythrocyte sedimentation rate and 25.84% had a normal C-reactive protein level. The lumbar spine was the most commonly involved spinal site (44.77%), followed by the thoracic spine (43.60%). All of the patients underwent chemotherapy, and 77.10% of patients underwent surgery. Most of the patients were cured, with the exception of 2.19% of patients who discontinued chemotherapy after early improvement of clinical status. Spinal TB is still a major public health problem in southwest China. Chemotherapy and surgery can yield satisfactory outcomes with timely diagnosis and long-term treatment. It is urgent to increase the attention paid to spinal TB and improve knowledge of this disease among the general public, especially in southwest China. [Orthopedics. 2017; 40(6):e1017-e1023.]. Copyright 2017, SLACK Incorporated.

Entities:  

Mesh:

Year:  2017        PMID: 29058758     DOI: 10.3928/01477447-20171012-03

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  6 in total

1.  [Polymethylmethacrylate-augmented screw fixation in treatment of senile thoracolumbar tuberculosis combined with severe osteoporosis].

Authors:  Qingda Li; Hao Chen; Tuanjiang Liu; Limin He; Peng Liu; Yuanting Zhao; Jinpeng Du; Peng Zou; Zhengping Zhang; Baorong He; Junsong Yang; Dingjun Hao
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-12-15

2.  Comparison of three surgical approaches for thoracolumbar junction (T12-L1) tuberculosis: a multicentre, retrospective study.

Authors:  Yanping Zeng; Peng Cheng; Jiulin Tan; Zhilin Li; Yuan Chen; Li Tao Li; Yonghong Zheng; Gaoju Wang; Jianzhong Xu; Zehua Zhang
Journal:  BMC Musculoskelet Disord       Date:  2019-11-09       Impact factor: 2.362

3.  Multi-drug resistant spinal tuberculosis-epidemiological characteristics of in-patients: a multicentre retrospective study.

Authors:  S Yang; Y Yu; Y Ji; D J Luo; Z Y Zhang; G P Huang; F Y He; W J Wu; X P Mou
Journal:  Epidemiol Infect       Date:  2020-01-27       Impact factor: 2.451

4.  Analysis of Clinical Characteristics of 556 Spinal Tuberculosis Patients in Two Tertiary Teaching Hospitals in Guangxi Province.

Authors:  Hao Zeng; Yingfang Liang; Jiaguo He; Liyi Chen; Haixia Su; Simi Liao; Sichun Huang; Hongyu Qin
Journal:  Biomed Res Int       Date:  2021-12-10       Impact factor: 3.411

5.  The efficacy of allograft bone using titanium mesh in the posterior-only surgical treatment of thoracic and thoracolumbar spinal tuberculosis.

Authors:  Bingjin Wang; Wenbin Hua; Wencan Ke; Yukun Zhang; Xianlin Zeng; Cao Yang
Journal:  BMC Surg       Date:  2020-06-12       Impact factor: 2.102

6.  Preliminary experience in treating thoracic spinal tuberculosis via a posterior modified transfacet debridement, instrumentation, and interbody fusion.

Authors:  Yun-Peng Huang; Jian-Hua Lin; Xiao-Ping Chen; Gui Wu; Xuan-Wei Chen
Journal:  J Orthop Surg Res       Date:  2018-11-20       Impact factor: 2.359

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.